Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. reports developments across a diversified life sciences, diagnostics, genomics and consumer health portfolio. Recurring company updates include the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity tied to legacy COVID-19 testing receivables, and Nebula Genomics, including the DNA Complete direct-to-consumer whole genome sequencing platform.
PRPH news also covers capital-structure actions, convertible debt conversions, financing discussions, operating and financial results, governance matters, and the company’s trading-status transition from Nasdaq and the Pink Sheets to the OTC market. These updates frame ProPhase as an OTC-traded healthcare issuer with diagnostic, genomic data, consumer health, and receivables-related assets.
ProPhase Labs, Inc. (NASDAQ: PRPH) has successfully closed a $10 million unsecured debt financing through two promissory notes. Each note matures in three years and accrues 10% annual interest, payable quarterly. Lenders can convert up to $3 million of the notes into common stock at a price of $3.00 per share after 13 months. The funds will be allocated for working capital, product development, and potential acquisitions. The CEO emphasized existing working capital of about $10 million will enhance business opportunities.
ProPhase Labs, Inc. reported net sales of $3.6 million for Q2 2020, an increase from $1.7 million in Q2 2019. The company achieved net income of $70,000 ($0.01 per share), reversing a net loss of $1.2 million ($0.11 per share) year-over-year. For the first half of 2020, net sales totaled $5.5 million, up from $4.0 million in the prior year, with a reduced net loss of $0.7 million compared to $2.3 million. This improvement stemmed from a rise in third-party orders and reductions in costs across various expense categories.
ProPhase Labs, Inc. (NASDAQ: PRPH) reported Q1 2020 net sales of $1.9 million, down from $2.3 million in Q1 2019. The net loss narrowed to $809,000 or ($0.07) per share compared to a net loss of $1.0 million or ($0.09) per share the previous year. Contributing factors included a $430,000 decline in sales due to reduced customer demand, offset by decreased costs in administration ($206,000), marketing ($96,000), and R&D ($35,000). Additionally, the Company released $4.8 million from escrow following a resolved claim with Mylan on May 4, 2020.